Genetics Generation Advancement (GGA) announced yesterday (16th) that it has signed a strategic cooperation agreement with Lightest Biomedical, a subsidiary of Genomics BioSci & Tech. (GBT), to jointly establish a smart laboratory with AI scalability and compliance management capabilities. This initiative aims to accelerate the development of Lightest Biomedical’s new antibiotics and novel drugs for Parkinson’s disease, with an Investigational New Drug (IND) application to the U.S. expected by 2026.

GGA General Manager Ching-Yuan Kang noted that this is one of the few cases in Taiwan where AI and digital record systems are integrated at the early stages of drug development. This reflects Lightest Biomedical’s long-term strategy for improving drug development efficiency and managing digital assets. The structured experimental data accumulated through this process will also serve as valuable training datasets for AI models. This aligns with the global trend highlighted at this year’s BIO International Convention, where AI is increasingly embedded throughout the drug development pipeline—from biomarker discovery and trial design to patient stratification.

Kang added that the GGA Group is actively building a growing portfolio of “AI Foundry” success cases in drug development and life sciences. The company plans to expand its network of partners to construct a comprehensive smart laboratory ecosystem that includes R&D, process development, GMP-compliant electronic management systems, regulatory frameworks, and AI analytics. This ecosystem is designed to boost overall efficiency in moving new drugs from concept to market.

Lightest Biomedical was established in 2023 as a spin-off from GBT’s Advanced Technology Development Division. The company focuses on developing next-generation antibiotics, new drugs for Parkinson’s disease, and innovative biotechnology platforms.

Through its proprietary drug development platform, Lightest Biomedical has significantly shortened the early-stage development timeline. Several candidate drugs have already been successfully developed and are now progressing through preclinical toxicology studies.

Currently, Lightest Biomedical is prioritizing two key products. One is a new-generation antibiotic, for which a provisional application has been filed in the U.S., initiating the first wave of patent protection. The company plans to complete the patent application for the drug combination’s therapeutic indications by the end of this year.

Resource: 訊聯基因 打造智慧實驗室